Overview

Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function

Status:
COMPLETED
Trial end date:
2025-07-23
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate pharmacokinetics of HRS-1893 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.
Phase:
PHASE1
Details
Lead Sponsor:
Shandong Suncadia Medicine Co., Ltd.